HGF and neoplasm: Emibetuzumab inhibited both HGF-dependent and -independent tumor growth in mouse xenograft models.30 A recent first-in-human phase I clinical study tested single-agent emibetuzumab in patients with solid tumors and emibetuzumab in combination with erlotinib in patients with NSCLC (NCT01287546).31 No dose-limiting toxicities and adverse events were observed, and half-life was ~11 days.